BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G. Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers (Basel) 2021;13:2400. [PMID: 34063518 DOI: 10.3390/cancers13102400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Siewe N, Friedman A. Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: A mathematical model. Journal of Theoretical Biology 2023;556:111297. [DOI: 10.1016/j.jtbi.2022.111297] [Reference Citation Analysis]
2 Becker H, Castaneda-vega S, Patzwaldt K, Przystal JM, Walter B, Michelotti FC, Canjuga D, Tatagiba M, Pichler B, Beck SC, Holland EC, la Fougère C, Tabatabai G. Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. Brain Sciences 2022;12:1426. [DOI: 10.3390/brainsci12111426] [Reference Citation Analysis]
3 Patysheva M, Frolova A, Larionova I, Afanas'ev S, Tarasova A, Cherdyntseva N, Kzhyshkowska J. Monocyte programming by cancer therapy. Front Immunol 2022;13:994319. [DOI: 10.3389/fimmu.2022.994319] [Reference Citation Analysis]
4 Aquilanti E, Wen PY. Current therapeutic options for glioblastoma and future perspectives. Expert Opinion on Pharmacotherapy. [DOI: 10.1080/14656566.2022.2125302] [Reference Citation Analysis]
5 Wu M, Shi Y, Zhu L, Chen L, Zhao X, Xu C. Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword. Life (Basel) 2022;12:1225. [PMID: 36013403 DOI: 10.3390/life12081225] [Reference Citation Analysis]
6 Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C. Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol 2022;13:844142. [PMID: 35874717 DOI: 10.3389/fimmu.2022.844142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Erne E, Anderle N, Schmees C, Stenzl A. Patientenabgeleitete Mikrotumoren. Urologie 2022;61:739-744. [DOI: 10.1007/s00120-022-01851-2] [Reference Citation Analysis]
8 Anderle N, Koch A, Gierke B, Keller AL, Staebler A, Hartkopf A, Brucker SY, Pawlak M, Schenke-Layland K, Schmees C. A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. Cancers (Basel) 2022;14:2895. [PMID: 35740561 DOI: 10.3390/cancers14122895] [Reference Citation Analysis]
9 Pang L, Khan F, Heimberger AB, Chen P. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer 2022:S2405-8033(22)00097-8. [PMID: 35624002 DOI: 10.1016/j.trecan.2022.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xu Z, Chen X, Song L, Yuan F, Yan Y. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis. Front Immunol 2022;13:834595. [PMID: 35281049 DOI: 10.3389/fimmu.2022.834595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Barca C, Foray C, Hermann S, Herrlinger U, Remory I, Laoui D, Schäfers M, Grauer OM, Zinnhardt B, Jacobs AH. The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Front Immunol 2021;12:787307. [PMID: 34950148 DOI: 10.3389/fimmu.2021.787307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Waibl Polania J, Lerner EC, Wilkinson DS, Hoyt-Miggelbrink A, Fecci PE. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Front Immunol 2021;12:777073. [PMID: 34868044 DOI: 10.3389/fimmu.2021.777073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ruoff F, Henes M, Templin M, Enderle M, Bösmüller H, Wallwiener D, Brucker SY, Schenke-layland K, Weiss M. Targeted Protein Profiling of In Vivo NIPP-Treated Tissues Using DigiWest Technology. Applied Sciences 2021;11:11238. [DOI: 10.3390/app112311238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Becker L, Janssen N, Layland SL, Mürdter TE, Nies AT, Schenke-Layland K, Marzi J. Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring. Cancers (Basel) 2021;13:5682. [PMID: 34830837 DOI: 10.3390/cancers13225682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ordentlich P. Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. Semin Immunol 2021;:101514. [PMID: 34776301 DOI: 10.1016/j.smim.2021.101514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Anderle N, Koch A, Gierke B, Keller A, Staebler A, Hartkopf A, Brucker SY, Pawlak M, Schenke-layland K, Schmees C. A platform of patient-derived microtumors identifies therapeutic vulnerabilities in ovarian cancer.. [DOI: 10.1101/2021.11.10.468007] [Reference Citation Analysis]